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Optimizing the management of hereditary haemochromatosis:
the value of MRI R2* quantification to predict and monitor
body iron stores
Hereditary haemochromatosis (HH) is a major cause of iron
overload. Without therapeutic intervention, HH patients are
at risk of severe tissue damage due to iron toxicity. HH-
related morbidity and mortality can be effectively reduced by
regular venesection (Niederau et al, 1985; Crosby, 1991), in
the form of a course of weekly intensive phlebotomies (IPh)
to deplete iron stores, followed by maintenance phlebotomies
(MPh) to prevent iron re-accumulation (European Associa-
tion for the Study of the Liver, 2010).
In spite of being a well-accepted, efficient and safe proce-
dure, phlebotomies may raise concerns regarding limitations
of patients’ daytime activities, decreasing their quality of life
(Brissot et al, 2010). To manage patient expectation at diag-
nosis and optimize treatment compliance, it is important to
predict the amount of mobilised iron and expected IPh dura-
tion, and to define reliable and safe endpoints for serum fer-
ritin (SF) levels during the MPh. In this setting, low SF
values (50–100 lg/l are usually advocated in clinical practice
(European Association for the Study of the Liver, 2010),
although normal SF (males: <300 lg/l; females: <200 lg/l)
have also been proposed (Vanclooster et al, 2016). Whether
iron re-accumulation differs according to different SF end-
points has not been reported to date.
We have recently implemented a 3 Tesla multi-echo
chemical shift-encoded gradient-echo magnetic resonance
(MECSE-MR) sequence, with high accuracy to simultane-
ously quantify liver steatosis, assessed as proton density fat
fraction (PDFF), and iron overload, assessed by R2* mea-
surements (Martı-Bonmatı et al, 2011; Franca et al, 2017a,b).
The same images also allow evaluation of the distribution of
iron deposits in different abdominal tissues (Franca et al,
2017b). This method might be useful for predicting mobiliz-
able total body iron stores (TBIS) during IPh and for assess-
ing liver iron re-accumulation in MPh.
We recruited 48 phenotypically and genetically well-char-
acterized HH patients (39 males, 15 females; age 19–80 years;
12 receiving IPh and 38 under MPh, 2 of which were also
tested during IPh) and 21 apparently healthy controls
(12 males, 9 females; age 20–77 years).
TBIS were quantified in all 12 HH patients undergoing
IPh, as previously described (Porto et al, 1997), considering
the total amount of iron (in grams) removed by phle-
botomies from the date of MR examination until iron deple-
tion, defined as SF <50 lg/l. As patients were recruited at
different IPh stages (3 of them had a second MR examina-
tion after total depletion), the calculated TBIS values ranged
from 0 to 123 g. Notably, there was no significant correla-
tion between initial SF values (retrieved from patients’ data
at diagnosis) and the TBIS quantified by phlebotomy
(P = 0578), possibly due to the generally poor specificity of
high SF values, and the fact that, at diagnosis, values were
distributed within a limited range of severe iron overload.
Nevertheless, SF values determined at several time points
during iron depletion (i.e. with a wide range of values from
iron overload to iron depletion) were significantly correlated
with the calculated TBIS at the same time points
(RS = 0916, P < 001). Therefore, SF appeared to be a good
marker for monitoring iron depletion during IPh but could
not predict TBIS at diagnosis.
Using the data from the patients undergoing IPh, a stepwise
regression analysis was performed considering TBIS as depen-
dent variable, taking gender, age and all R2* tissue determina-
tions (liver, pancreas, spleen and vertebra bone marrow) as
independent variables (Table I). Forward and backward selec-
tion methods were applied to select the most parsimonious
model for predicting TBIS. The best regression model included
two predictors: liver R2* (F-to-enter = 725553, P < 00001)
and pancreas R2* (F-to-enter = 195504, P = 00008), with a
coefficient of determination of R2 = 942% (P < 001),
being expressed by the equation: TBIS = 0006 9 Liver
R2* + 0009 9 Pancreas R2*  1064. This new TBIS vari-
able was designated FELIPA, for iron (FErrum) in liver (LI)
and pancreas (PA).
Tissue iron quantification and distribution using R2*
metrics was next assessed in the group of 38 patients under-
going MPh every 3 months for at least 2 years, with no
change in intervention provided that SF values were main-
tained below the normal upper limit (males: 300 lg/l;
females: 200 lg/l). In this group, SF values ranged from 9 to
300 lg/l, and were, in general, significantly correlated with
hepatic iron deposits as assessed by liver R2* (RS = 0611,
P < 005). No significant correlation was found between
time since the end of IPh (range: 2–28 years) and SF or liver
R2* values.
The “accepted standard” SF threshold of 99 lg/l (Euro-
pean Association for the Study of the Liver, 2010) identified
patients with hepatic R2* higher than 48 Hz (the average
R2* value in controls), with 875% sensitivity and 857%
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specificity. A SF threshold of 160 lg/l, in turn, identified
patients with hepatic R2* higher than 81 Hz (the highest
R2* value in controls) with 100% sensitivity and 793%
specificity, thus supporting this threshold as a safe value to
assume hepatic R2* within normal limits (Fig 1A). Impor-
tantly, liver steatosis, defined as PDFF >48% (Franca et al,
2017a), was a common finding (67% of MPh patients), par-
ticularly when SF was >160 lg/l(80% of these patients)
(Fig 1B). This association of liver steatosis with high SF val-
ues can be interpreted as steatosis itself giving rise to an
increased SF independently of iron load, but it does not rule
out the hypothesis that minimal iron toxicity might also be
involved in the pathogenesis of steatosis.
Our study had limitations. The small number of IPh
patients to quantify TBIS hampers the construction of pre-
dictive models extensible to larger populations. Although
methodological constraints limit iron quantification above a
certain load, the iron range observed in this study corre-
sponds to the range of values where more precision is needed
in daily clinical practice. A SF threshold for normal liver R2*
can be very useful as a practical cut-off, but it does not
determine whether iron-induced tissue damage could still be
occurring (e.g., as a result of abnormally increased non-
transferrin-bound iron).
In conclusion, MR determined R2* measurements as sur-
rogate markers of TBIS in patients with HH are feasible.
Table I. Regression results. Regression results showing different test models to estimate total body iron stores (TBIS; dependent variable) using
the different tissue R2* measurements (liver, pancreas, spleen and bone marrow), age and gender as independent variables. The best-fitted model
(with the highest adjusted-R2, “Model 2”) has two significant predictors (liver R2* and pancreas R2*), being expressed as TBIS = 0006 9 Liver
R2* + 0009 9 Pancreas R2*  1064.
Independent variable
Regression model
Model 1 Model 2 Model 3
Liver R2* 0006* (0003, 0009) 0006** (0005, 0007) 0006** (0005, 0007)
Pancreas R2* 0008* (0004, 0013) 0009** (0006, 0013) 0009** (0005, 0012)
Spleen R2* 0012 (0043, 0019)
Bone marrow R2* 0010 (0010, 0030)
Age 0009 (0051, 0032) 0010 (0046, 0027)
Gender 0807 (2091, 0477) 0807 (1867, 0547)
Constant 0472 (4066, 3122) 1064* (1652, 0476) 1121 (1680, 1922)
R2 0956 0942 0949
Adjusted R2 0923 0932 0929
*P < 005; **P < 001
Fig 1. (A) Scatter plot of serum ferritin (SF) values and liver R2* values in patients with hereditary haemochromatosis (HH) under maintenance
phlebotomy (MPh). Vertical lines indicate the SF cut-off value of 160 lg/l; the horizontal line indicates the highest hepatic R2* value in healthy
controls, as reference. All patients with SF <160 lg/l had hepatic iron in the same range as healthy controls (100% sensitivity, 793% specificity).
(B) Scatter plot of liver steatosis (proton density fat fraction [PDFF] values) and iron deposits (R2* values) in HH patients under MPh, grouped
by SF values below or above the cut-off 160 lg/l. Patients with SF >160 lg/l had the highest hepatic R2* and PDFF values, suggesting higher
accumulation of iron and steatosis, respectively.
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FELIPA, a new variable obtained from liver and pancreas
R2* measurements, was correlated with TBIS, calculated by
quantitative phlebotomies. FELIPA might be a new useful
tool for estimating the severity of iron burden and managing
patients’ expectations on IPh duration. Liver R2* measure-
ments in HH patients undergoing MPh suggest a best SF
cut-off value of 160 lg/l to discriminate between patients
with normal iron stores and those in whom there is iron
re-accumulation.
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